Taylor Ben R 4

What Happened
Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), was granted two awards totaling 470,533 restricted stock units (446,279 and 24,254 RSUs) on Feb 6, 2026 (awarded at $0.00). On the same date 11,400 shares were disposed of at $3.98 per share to satisfy tax withholding obligations, generating $45,372. The large RSU grants are acquisitions (awards), while the 11,400-share disposition is a routine tax-withholding action rather than an open-market sale.

Key Details

• Transaction dates: Feb 6, 2026 (reported on Form 4 filed Feb 10, 2026).
• Grants: 446,279 RSUs and 24,254 RSUs, acquisition price $0.00.
• Withholding/disposition: 11,400 shares disposed at $3.98 each for total $45,372 (coded F).
• Vesting notes: One grant vests 1/16th on May 15, 2026 and quarterly thereafter (F1); the smaller grant vested immediately on the grant date (F2).
• Tax withholding: The 11,400 shares were withheld by the issuer to cover tax obligations in a net settlement of RSUs (F3).
• Shares owned after the transaction: Not specified in the filing.
• Filing timing: Form dated Feb 10 covering Feb 6 transactions — appears to be filed four days after the transaction; Form 4s are normally due within two business days, so this may be later than typical.

Context

• These transactions include awards (A) — new RSUs granted to the CFO — and a tax-withholding disposition (F). RSU awards are a form of compensation/acquisition, not an open-market purchase.
• The 11,400-share disposition was to satisfy withholding obligations (net settlement), not an indicative open-market sale of shares for investment reasons.
• For retail investors, awards increase insider exposure to the company over time as RSUs vest; tax-withholding disposals are common and routine.